Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B
Department of Histopathology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
Histopathology. 2009 Jan;54(2):248-53. doi: 10.1111/j.1365-2559.2008.03185.x.
To validate the use of the silver-enhanced in situ hybridization (SISH) technique in assessing HER2 status of breast carcinoma in excision biopsy specimens, and to assess its reliability in determining HER2 status in core biopsy specimens.
Routinely processed paraffin sections of 65 excised breast carcinomas and 56 available preoperative core biopsy specimens from the same patients were selected from the archives for testing with the SISH technique using the automated Ventana Benchmark XT machine. For each case, two sections were used, one for the assessment of HER2 gene amplification and the other for assessment of chromosome 17. Of the 65 excision specimens tested, sections of 53 cases were also available for fluorescence in situ hybridization (FISH) examination. HER2 gene amplification was detected by SISH in 14 (21%) out of 65 excision specimens and in eight (14%) out of 56 core biopsy specimens. The results of SISH and FISH were identical in 50 (94%) out of the 53 excision cases examined by the two techniques. Two cases were SISH-, FISH+, and one case was the other way round. SISH results of core biopsy specimens and corresponding excision biopsy specimens were identical in 50 (89%) out of 56 cases. Four cases (7%) were SISH- in cores but positive in excision specimens, whereas two cases were the other way round.
The results validate the use of the SISH technique for assessing HER2 status of excised breast carcinoma tissue sections. The results are comparable to those obtained with FISH, but SISH has the advantage of having a permanent end result that can be visualized by an ordinary light microscope. There is a reasonable 89% concordance between SISH results obtained in core and excision biopsy specimens. However, it may be prudent to postpone doing SISH, if possible, until sections of the resected specimen are available, as these seem to be more reliable.
验证银增强原位杂交（SISH）技术在评估切除活检标本中乳腺癌HER2状态的应用，并评估其在确定粗针活检标本中HER2状态的可靠性。
从存档中选取65例切除的乳腺癌常规处理石蜡切片以及来自同一患者的56份可用术前粗针活检标本，使用自动Ventana Benchmark XT机器采用SISH技术进行检测。对于每个病例，使用两张切片，一张用于评估HER2基因扩增，另一张用于评估17号染色体。在检测的65例切除标本中，53例的切片也可用于荧光原位杂交（FISH）检查。通过SISH在65例切除标本中的14例（21%）以及56例粗针活检标本中的8例（14%）检测到HER2基因扩增。在两种技术检测的53例切除病例中，SISH和FISH结果在50例（94%）中一致。2例为SISH阴性、FISH阳性，1例相反。在56例病例中，粗针活检标本和相应切除活检标本的SISH结果在50例（89%）中一致。4例（7%）粗针标本SISH阴性但切除标本阳性，而2例相反。
结果验证了SISH技术用于评估切除的乳腺癌组织切片HER2状态的应用。结果与FISH相当，但SISH具有可通过普通光学显微镜观察到永久最终结果的优势。粗针活检标本和切除活检标本获得的SISH结果之间有合理的89%一致性。然而，如果可能的话，谨慎做法是在获得切除标本切片后再进行SISH检测，因为这些切片似乎更可靠。
